Skip to main content
Livermore
Livermore
ZHEN

Citadel Advisors LLC

SEC CIK
0001423053
Latest filing
Sep 1, 2026

RARE holding history

Ultragenyx Pharmaceutical Inc. in every 13F filed by Citadel Advisors LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

RARE overviewAll 13F holders of RAREFull Q2 2026 holdings

Shares (Q2 2026)
210,531
Value
$7.03M
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of RARE by Citadel Advisors LLC, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026210,531$7.03M<0.1%−1,904,960−90.0%ReducedHolders
Q1 20262,115,491$44.3M<0.1%−210,634−9.1%ReducedHolders
Q4 20252,326,125$53.5M<0.1%+1,995,172+602.9%AddedHolders
Q3 2025330,953$9.96M<0.1%+293,326+779.6%AddedHolders
Q2 202537,627$1.37M<0.1%−218,922−85.3%ReducedHolders
Q1 2025256,549$9.29M<0.1%−29,630−10.4%ReducedHolders
Q4 2024286,179$12.0M<0.1%+238,226+496.8%AddedHolders
Q3 202447,953$2.66M<0.1%−125,995−72.4%ReducedHolders
Q2 2024173,948$7.15M<0.1%−119,357−40.7%ReducedHolders
Q1 2024293,305$13.7M<0.1%+93,251+46.6%AddedHolders
Q4 2023200,054$9.57M<0.1%+198,653+14,179.4%AddedHolders
Q3 20231,401$49.9K<0.1%−275,282−99.5%ReducedHolders
Q2 2023276,683$12.8M<0.1%−281,133−50.4%ReducedHolders
Q1 2023557,816$22.4M<0.1%+337,840+153.6%AddedHolders
Q4 2022219,976$10.2M<0.1%+36,970+20.2%AddedHolders
Q3 2022183,006$7.58M<0.1%−834,297−82.0%ReducedHolders
Q2 20221,017,303$60.7M0.1%−297,729−22.6%ReducedHolders
Q1 20221,315,032$95.5M0.1%−128,415−8.9%ReducedHolders
Q4 20211,443,447$121.4M0.1%−39,703−2.7%ReducedHolders
Q3 20211,483,150$133.8M0.1%−373,329−20.1%ReducedHolders
Q2 20211,856,479$177.0M0.2%+911,966+96.6%AddedHolders
Q1 2021944,513$107.5M0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.